Rhumbline Advisers lifted its position in shares of Hill-Rom Holdings, Inc. (NYSE:HRC) by 40.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 183,809 shares of the medical technology company’s stock after buying an additional 52,630 shares during the quarter. Rhumbline Advisers’ holdings in Hill-Rom were worth $16,276,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of HRC. Raymond James & Associates boosted its holdings in Hill-Rom by 28.1% in the second quarter. Raymond James & Associates now owns 7,869 shares of the medical technology company’s stock valued at $687,000 after acquiring an additional 1,728 shares during the last quarter. Advisors Asset Management Inc. boosted its holdings in Hill-Rom by 557.8% in the second quarter. Advisors Asset Management Inc. now owns 6,749 shares of the medical technology company’s stock valued at $589,000 after acquiring an additional 5,723 shares during the last quarter. United Services Automobile Association boosted its holdings in Hill-Rom by 7.7% in the second quarter. United Services Automobile Association now owns 21,534 shares of the medical technology company’s stock valued at $1,881,000 after acquiring an additional 1,544 shares during the last quarter. State of Alaska Department of Revenue boosted its holdings in Hill-Rom by 14.5% in the third quarter. State of Alaska Department of Revenue now owns 7,674 shares of the medical technology company’s stock valued at $724,000 after acquiring an additional 974 shares during the last quarter. Finally, CAPROCK Group Inc. acquired a new position in Hill-Rom in the third quarter valued at $211,000. Institutional investors own 86.96% of the company’s stock.

Shares of HRC opened at $102.91 on Tuesday. The stock has a market cap of $6.84 billion, a price-to-earnings ratio of 21.67, a P/E/G ratio of 1.45 and a beta of 0.95. Hill-Rom Holdings, Inc. has a 12 month low of $79.36 and a 12 month high of $105.78. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.25 and a current ratio of 1.70.

Hill-Rom (NYSE:HRC) last released its quarterly earnings results on Friday, January 25th. The medical technology company reported $1.02 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.98 by $0.04. Hill-Rom had a return on equity of 21.23% and a net margin of 7.21%. The business had revenue of $683.50 million for the quarter, compared to analysts’ expectations of $676.39 million. During the same quarter in the previous year, the firm posted $0.92 earnings per share. The company’s revenue was up 2.1% compared to the same quarter last year. As a group, equities research analysts predict that Hill-Rom Holdings, Inc. will post 5.06 earnings per share for the current fiscal year.

In related news, SVP Andreas G. Frank sold 7,454 shares of the business’s stock in a transaction dated Wednesday, November 28th. The stock was sold at an average price of $95.76, for a total value of $713,795.04. Following the transaction, the senior vice president now owns 27,224 shares in the company, valued at $2,606,970.24. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 0.73% of the company’s stock.

A number of research analysts have commented on HRC shares. ValuEngine upgraded Hill-Rom from a “hold” rating to a “buy” rating in a research note on Saturday, January 19th. Morgan Stanley reduced their price objective on Hill-Rom from $100.00 to $98.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 2nd. Raymond James boosted their price objective on Hill-Rom from $100.00 to $105.00 and gave the stock an “outperform” rating in a research note on Monday, November 5th. Barclays started coverage on Hill-Rom in a research note on Monday, October 15th. They set an “equal weight” rating and a $95.00 price objective on the stock. Finally, UBS Group started coverage on Hill-Rom in a research note on Tuesday, November 27th. They set a “buy” rating and a $115.00 price objective on the stock. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company. Hill-Rom presently has an average rating of “Buy” and a consensus price target of $102.67.

WARNING: This report was first reported by Daily Political and is owned by of Daily Political. If you are accessing this report on another website, it was stolen and republished in violation of United States & international trademark and copyright legislation. The legal version of this report can be viewed at https://www.dailypolitical.com/2019/02/12/hill-rom-holdings-inc-hrc-stake-raised-by-rhumbline-advisers.html.

About Hill-Rom

Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.

Featured Article: Book Value Per Share – BVPS

Want to see what other hedge funds are holding HRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hill-Rom Holdings, Inc. (NYSE:HRC).

Institutional Ownership by Quarter for Hill-Rom (NYSE:HRC)

Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.